Sera Prognostics Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the PRETRM® Test-and-Treat Strategy Across Diverse Populations November 15, 2022
Banner Health, Sera Prognosics Team Up to Provide PreTRM® Test to Cover Pregnant Members September 22, 2022
Sera Prognostics Presents Data Demonstrating the Health & Economic Benefit of PRETRM® Testing at Ispor Annual Meeting May 20, 2022
Sera Prognostics and Newborn Foundation Partner to Reduce Risks Associated with Preterm Birth and Improve Health Equity Through the “Every Mother, Every Baby” Project May 5, 2022
Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting March 18, 2022
Sera Prognostics Announces Collaboration to Help Underserved Communities Make Informed Decision about Prenatal Health November 4, 2021
Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit September 15, 2021
Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility August 17, 2021
